v3.24.1.1.u2
Revenue Interest Financing Liability - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 28, 2023
Oct. 31, 2022
May 03, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Revenue Interest Financing Liability [Line Items]              
Investors right to receive royalties termination description       The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for Erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.      
Investors receipt description       If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.      
Default obligation description       Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025 and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.      
Gross proceeds       $ 0   $ 175,000  
Transaction costs       0   2,325  
Net proceeds           172,700  
Revenue interest financing liability       319,006   306,927 $ 109,525
Interest expense with revenue interest finance liability       $ 12,147 $ 5,200 $ 24,727  
Revenue Interest Financing Agreement              
Revenue Interest Financing Liability [Line Items]              
Percentage of investor share of royalty in net sales     10.00%        
Percentage of aggregate payments on investment amount to investors on net sales     200.00%        
Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025              
Revenue Interest Financing Liability [Line Items]              
Percentage of aggregate payment on investment amount to investors     1.30%        
Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028              
Revenue Interest Financing Liability [Line Items]              
Percentage of aggregate payment on investment amount to investors     1.65%        
Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028              
Revenue Interest Financing Liability [Line Items]              
Percentage of aggregate payments on investment amount to investors on net sales     2.00%        
Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement              
Revenue Interest Financing Liability [Line Items]              
Funds received from initial closing     $ 100,000        
Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter of 2024              
Revenue Interest Financing Liability [Line Items]              
Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis $ 160,000            
Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member] | Joinder Agreement              
Revenue Interest Financing Liability [Line Items]              
Additional funding achievement of sales milestone   $ 25,000          
Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member] | Joinder Agreement Additional Funding Upon FDA Approval or During the Fourth Quarter of 2023              
Revenue Interest Financing Liability [Line Items]              
Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis   $ 15,000          
Maximum | Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement              
Revenue Interest Financing Liability [Line Items]              
Investors funding amount     $ 260,000        
Minimum | Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028              
Revenue Interest Financing Liability [Line Items]              
Percentage of aggregate payment on investment amount to investors     100.00%        
Minimum | Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037              
Revenue Interest Financing Liability [Line Items]              
Percentage of aggregate payment on investment amount to investors     200.00%